300206 Edan Instruments, Inc.
- 12.37
- +0.11+0.90%
Edan Instruments, Inc. News
edan instruments, inc. (300206.SZ): The specific amount of funds received from Global Health Labs, Inc. and the Gates Foundation needs to be determined in batches according to the relevant circumstances.
Edan instruments, inc. (300206.SZ) announced that the company's stocks will be on November 21, 2024, and November 22...
Express News | Edan Instruments, Inc.: The operation of the company is normal.
edan instruments, inc. AI ultrasound project received further grant support, helping to improve maternal and child health.
Shenzhen, November 21, 2024 / USA Today / - Shenzhen Libang Precision Instruments Co., Ltd. (hereinafter referred to as the "Company") signed the "Main License, Development, and Commercialization Agreement" for the artificial intelligence ultrasound project with Global Health Labs, Inc (hereinafter referred to as "GH Labs") in Bellevue, Washington State, USA on March 14, 2024. For specific details, please refer to the voluntary disclosure by the company on March 15, 2024 on the Giant Tide Information website.
Edan instruments, inc. (300206.SZ): The Gates Foundation will provide a total grant of 2.65 million USD to the company.
Galunhui Nov. 20th | Edan Instruments, Inc. (300206.SZ) announced that the company, in collaboration with GHLabs, has completed the demand research, project planning, lightweight integration of artificial intelligence models, and software feature development for an economical handheld ultrasound device driven by ai. The project is currently in the stage of clinical data collection and performance optimization, meeting the established expectations of both parties. Based on the interim results of the current project and the expectations of the Bill and Melinda Gates Foundation (referred to as the Gates Foundation) for the project, further support will be provided to the company to develop new ultrasound solutions to assist midwives in the care of pregnant and parturient women.
Express News | edan instruments, inc.: Received 2.65 million dollars from the Gates fund to support the ai ultrasound project.
EDAN Unveils Latest Innovations for Global Healthcare at MEDICA 2024
Edan Instruments, Inc. (300206): The market promotion of the I500 blood gas analyzer is progressing smoothly as the company continues to advance its digitalization layout.
Event: On October 25, the company released the third quarter report of 2024: revenue of 1.382 billion yuan in the first three quarters of 2024, a year-on-year decrease of 9.29%; net income attributable to the parent company was 0.172 billion yuan, a year-on-year decrease
Edan Instruments, Inc. (300206.SZ): The second phase construction project is expected to be topped out around the Spring Festival.
Gelonghui November 4th, edan instruments, inc. (300206.SZ) stated on the investor interaction platform that the company's Phase II construction project is currently progressing smoothly and is expected to be topped out around the Chinese New Year. As for the specific commissioning time, it will depend on the project completion acceptance progress and subsequent business needs.
edan instruments, inc. (300206) 2024 third quarter report review: performance meets expectations, expecting growth to resume next year.
Event: According to the company's announcement, in the first three quarters of 2024, the company achieved total operating income of 1.382 billion yuan (-9.29%, indicating year-on-year growth rate, the same below), and a net income attributable to the parent company of 0.172 billion yuan (-27.41%), after deducting non-recurring items.
Libang Instruments: Report for the third quarter of 2024
edan instruments, inc. (300206.SZ) released its performance for the first three quarters, with a net income of 0.172 billion yuan, a decrease of 27.41%.
Edan Instruments, Inc. (300206.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters of the year reaching 1...
edan instruments, inc. (300206.SZ): The company's molecular diagnostic platform has the ability to detect monkeypox virus.
On September 6th, edan instruments, inc. stated on the investor interactive platform that the company's molecular diagnostic platform has the ability to detect monkeypox virus, but it has not yet obtained registration and certification for this product domestically and internationally. The company will continue to monitor the market demand for monkeypox virus and changes in regulatory policies. If there is an increase in clinical demand in the future, and there is a feasible fast-track emergency approval registration channel, the company will timely proceed with the registration and certification of relevant products.
edan instruments, inc. (300206.SZ): Currently, the ECG monitoring products mainly serve medical institutions.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform that Edan does have a solid accumulation in the field of ECG monitoring technology and has established a comprehensive ECG diagnostic business system, including static ECG, exercise ECG, and ambulatory ECG/blood pressure monitoring, and also provides comprehensive ECG network solutions. Currently, the company's ECG monitoring products mainly serve medical institutions. Of course, the company also sees the huge potential of the home medical instruments market and considers this as one of the key directions for future development. Therefore, the company is actively deploying in this field and plans to adjust its business and product strategies according to market demand and
Edan Instruments, Inc. (300206.SZ): Currently, it does not involve the development of smart wristbands or watches.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform on September 6th that the company is currently not involved in the development of smart bracelets and watches. The products currently included in the company's personal health care business include fetal Doppler products, pelvic floor rehabilitation products, neonatal pulse oximeter products, finger pulse oximeter products, and thermometer products. In the field of home blood pressure monitoring, the company is about to launch the high cost-effective HP10 and HP11 series blood pressure monitors equipped with medical-grade blood pressure algorithm (China NMPA registration has been completed), which greatly reduces the user's discomfort with its fast results, accurate measurement, and medical-grade algorithm.
Edan Instruments, Inc. (300206.SZ): The company's target for blood gas consumables in 2024 is to ship over 10 million pieces.
On August 30, 2024, edan instruments, inc. (300206.SZ) held a performance briefing on the sales of blood gas consumables in the first half of the year and the annual expectations. The company stated that its target for blood gas consumables in 2024 is to ship over 10 million pieces. As of the first half of 2024, the shipment of blood gas consumables was about 4.5 million pieces. With the drive of inventory and incremental instruments in the second half of the year, the company is confident in achieving this annual target.
Libang Instruments: 2024 Semi-Annual Report Summary
Libang Instruments: 2024 Semi-Annual Report
Express News | Edan Instruments, Inc.: Net income in the first half of the year decreased by 39.59% year-on-year.
edan instruments, inc. (300206.SZ): net income of 0.125 billion yuan in the first half of the year, a year-on-year decrease of 39.59%.
Edan Instruments, Inc. (300206.SZ) announced on August 29th that in the first half of 2024, it achieved a total operating income of 0.922 billion yuan, a year-on-year decrease of 15.39%; net income attributable to the parent company's shareholders was 0.125 billion yuan, a year-on-year decrease of 39.59%; and the basic earnings per share was 0.2158 yuan.
Edan Instruments, Inc. (300206.SZ) released its half-year performance, with a net income of 0.125 billion yuan, a decrease of 39.59%.
Edan Instruments, Inc. (300206.SZ) released its half-yearly report for 2024, during the reporting period, the company achieved revenue...
No Data
